Drug intelligence / Profile preview

NM49

Development stage: Preclinical
Lead developer: Numab Therapeutics
Modality: Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

**NM49** is a novel multi-specific antibody developed by Numab Therapeutics using their proprietary λ-Cap™ and MATCH™ platforms. It functions as a **macrophage engager**, designed to activate tumor-associated macrophage phagocytosis to enhance anti-tumor immune responses in oncology. Numab is conducting preclinical studies and CMC activities, with Ono Pharmaceutical holding an exclusive worldwide option to develop and commercialize, funding related expenses during the option period; Numab retains an opt-in right for US co-development.[2][3][7]

Targets

TAM (TAM receptor tyrosine kinases)

Beyond the preview

Go deeper on NM49.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NM49.

Explore the full profile